Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling

• Main Authors: Alexander Solms (Author), Matthias Frede (Author), Scott D. Berkowitz (Author), Anne Hermanowski‐Vosatka (Author), Dagmar Kubitza (Author), Wolfgang Mueck (Author), Theodore E. Spiro (Author), Stefan Willmann (Author), Xiaoyu Yan (Author), Liping Zhang (Author), Dirk Garmann (Author)
• Format: Book
• Published: Wiley, 2019-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Prothrombin time (PT) is a measure of coagulation status and was assessed in the majority of patients in the rivaroxaban phase II and III clinical trials as a pharmacodynamic marker. In the absence of sufficient phase III pharmacokinetic (PK) data to provide individual exposure measures for input in...